Skip to content
10-Q/A

Quarterly Report

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

0001193125-22-023438

← back to feed
Filed
Jan 31, 2022 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q3 2021 · Sep 30, 2021 −$729.5K
Cash And Equivalents Q3 2021 · Sep 30, 2021 $635.59K
Cash And Equivalents Q3 2021 · Dec 31, 2020 $1.37M
Stockholders Equity Q3 2021 · Sep 30, 2021 −$7.29M
Stockholders Equity Q3 2021 · Jun 30, 2021 −$9.02M
Stockholders Equity Q3 2021 · Mar 31, 2021 −$7.72M
Stockholders Equity Q3 2021 · Dec 31, 2020 −$10.54M
Current Liabilities Q3 2021 · Sep 30, 2021 $245.88K
Current Liabilities Q3 2021 · Dec 31, 2020 $236.52K
Total Liabilities Q3 2021 · Sep 30, 2021 $8.27M
Total Liabilities Q3 2021 · Dec 31, 2020 $12.41M
Current Assets Q3 2021 · Sep 30, 2021 $966.42K
Current Assets Q3 2021 · Dec 31, 2020 $1.87M
Total Assets Q3 2021 · Sep 30, 2021 $138.98M
Total Assets Q3 2021 · Dec 31, 2020 $139.87M
Sga Expense Q3 2021 · Sep 30, 2021 $339.23K
Sga Expense Q3 2021 · Sep 30, 2021 $821.71K
Net Income Q3 2021 · Sep 30, 2021 $1.73M
Net Income Q3 2021 · Sep 30, 2021 $3.25M
Net Income Q3 2021 · Jun 30, 2021 −$1.3M
Net Income Q3 2021 · Mar 31, 2021 $2.82M
Operating Income Q3 2021 · Sep 30, 2021 −$369.23K
Operating Income Q3 2021 · Sep 30, 2021 −$911.71K